title: Is it time to combine osteoporosis therapies?
authors.affiliation: Academic Unit of Bone Metabolism, Metabolic Bone Centre, Northern General Hospital, Sheffield S5 7AU, UK. r.eastell@sheffield.ac.uk
authors.forename: Richard
authors.initials: R
authors.lastname: Eastell
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Walsh
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D000069448:Denosumab; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D019379:Teriparatide / Q000008:administration & dosage*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D019379:Teriparatide; D000069448:Denosumab